MTIP
IOVA icon

Magee Thomson Investment Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Magee Thomson Investment Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1K Buy
+99
New +$726 ﹤0.01% 52

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magee Thomson Investment Partners's IOVA Position: Q1 2017 in Review

Magee Thomson Investment Partners opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2017: 99 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #52 among its holdings.

81 funds tracked by Wall St. Rank hold IOVA as of Q1 2017.

  • Magee Thomson Investment Partners held 99 shares of Iovance Biotherapeutics worth $1K as of Q1 2017.
  • Iovance Biotherapeutics was a new Magee Thomson Investment Partners position in Q1 2017.
  • Iovance Biotherapeutics made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #52 holding.
  • 81 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.